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Objectives: To report and analyse trends in antibiotic use in Dutch university hospitals, large teaching hospitals
and general hospitals over the period 2003 to 2009.
Methods: Data on the use of antibiotics and hospital resource indicators were obtained by distributing a ques-
tionnaire to all Dutch hospital pharmacies. Antibiotic use was expressed as the number of defined daily doses
(DDDs) per 100 patient-days, per 100 admissions and per 1000 inhabitants per day. The latter was achieved by
extrapolating sample data by means of imputation and up-scaling.
Results: From 2003 to 2009, the mean length of hospital stay decreased from 6.27 to 4.50 days (228%). Total
systemic antibiotic use significantly increased from 52.3 to 69.8 DDDs per 100 patient-days (P,0.001). Despite
the overall constant use when expressed in DDDs per 100 admissions, we found a significant increase in the
total use of piperacillin/tazobactam, cefazolin, ceftriaxone, meropenem, azithromycin, gentamicin, ciprofloxa-
cin and vancomycin. Mean total systemic use expressed in DDDs per 1000 inhabitants per day gradually
increased by 38% from 0.73 in 2003 to 1.01 in 2009.
Conclusions: Total hospital antibiotic consumption is still low in the Netherlands compared with other European
countries. Also, between 2003 and 2009 the use of antibiotics in individual hospitalized patients remained
stable. However, since they remained in the hospital for a shorter period of time, the number of DDDs per
100 patient-days increased. This results in an intensification of antibiotic treatment per hospital bed, leading
to a possible increase in selection pressure towards resistance. This may create a problem for future patients.
To limit the emergence and transmission of antimicrobial-resistant bacteria, effective antibiotic stewardship is
essential.
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Introduction
In 1996 the Working Party on Antibiotic Policy (SWAB) was
founded by the Dutch Society for Medical Microbiology, the
Society for Infectious Diseases and the Dutch Association of Hos-
pital Pharmacists. SWAB’s mission is to manage, limit and
prevent the emergence of resistance to antimicrobial agents
among medically important species of microorganisms in the
Netherlands, thereby contributing to the proper care of patients
in this country. The activities of SWAB are supported by a struc-
tural grant from the Dutch Ministry of Health, Welfare and Sport.
SWAB’s Working Group on Surveillance of Antimicrobial Use col-
lects data on national antibiotic use in hospitals.1 Janknegt
et al.2 conducted a study on hospital antibiotic use over the
period 1991–96. Liem et al.3 analysed trends in antibiotic use
over the period 1997–2002. Since 2003, data on antibiotic use
are presented in SWAB’s annual report, called NethMap.4 In the
present study, we report on antibiotic use in Dutch hospitals
during the period 2003–09. In line with previous reports, we
expressed hospital antibiotic use in defined daily doses (DDDs)
per 100 patient-days and DDDs per 100 admissions.2,3,5 More-
over, for the first time, we expressed hospital antibiotic use in
DDDs per 1000 inhabitants per day, which is a valuable addition-
al unit of measurement for cross-national comparison.6
Methods
All Dutch hospitals—8 university hospitals, 27 large teaching hospitals
[providing highlyspecialized medical care (e.g. heart surgery, neurosurgery,
in vitro fertilization and high-level intensive care) that lies between that of a
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university medical centre and that of a general hospital]7 and 62 general
hospitals—were asked to participate in SWAB’s national surveillance
system. Data on the use of antibiotics in acute care hospitals between
2003 and 2009 were collected by means of a questionnaire distributed
to all Dutch hospital pharmacies by SWAB (please see the Supplementary
data at JACOnline for an example of the questionnaire, in Dutch, as well as
an English translation). Data from inpatient wards as well as day care wards
were included, whereas outpatient use and dispensing to nursing homes
were excluded from the data report. Pharmacies were requested to
report on the annual consumption of antibiotics of different (sub)classes
of the Anatomical Therapeutic Chemical (ATC) classification system. For
this report, only data from the J01 subgroup were used, expressed as
DDDs per 100 patient-days, per 100 admissions and per 1000 inhabitants
per day. The ATC/DDD classification from the WHO, version 2010, was used
to calculate the number of DDDs of the various antibiotics.8 The DDD is
defined as the assumed average maintenance dose per day for a drug
used for its main indication in adults.
For each hospital, the annual number of bed-days and admissions
was recorded. The number of patient-days was obtained by subtracting
the number of admissions from the number of bed-days, as the
number of bed-days overestimates actual treatment-days by including
both the day of admission and the day of discharge.3 The mean length
of stay was calculated by dividing the number of patient-days by the
mean number of admissions.3 Data on the annual number of inhabitants
in the Netherlands were obtained from Statistics Netherlands (CBS).9
Statistical analysis
Trend analysis
For the period 2003–09, an overall pooled mean (i.e. weighted mean)
was calculated for each year by aggregating data on antibiotic use and
patient-days from all the hospitals in our sample. Drug utilization was
compared between hospitals and over time by a mixed model for
repeated measurements. The response variables were the number of
DDDs per 100 patient-days and the number of DDDs per 100 admissions.
Changes in the mean number of admissions, mean number of patient-
days and mean length of hospital stay between 2003 and 2009 were cal-
culated using the Mann–Whitney U-test with continuous variables.
P values ,0.05 were considered statistically significant in all analyses.
SAS 9.3 (SAS Institute, NC, USA) or SPSS version 18.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical calculations.
DDDs per 1000 inhabitants per day
Hospital consumption data and corresponding hospital statistics were
used to estimate total hospital consumption in the Netherlands. First,
an algorithm combining linear interpolation, first value carried backward
and last value carried forward was used, followed by up-scaling of the
dataset to the total number of university hospitals, large teaching hospi-
tals or general hospitals in the Netherlands.7 Finally, hospital antibiotic
consumption was expressed as DDDs per 1000 inhabitants per day. Stat-
istical analyses were performed using R 2.13.1 (R Foundation for Statistic-
al Computing, Vienna, Austria).10 Because these hospital consumption
data were partially observed and partially interpolated, a trend analysis
was not performed.
Results
Hospital resource indicators
The number of hospitals that issued data on antibiotic use varied
from 39.4% in 2007 to 63.6% in 2003. A total of 86 out of 97
hospitals participated for ≥1 year between 2003 and 2009. Of
these 86 hospitals, 48% participated for ≥5 years. Only 13 hos-
pitals participated every year. Most of the hospitals that did
not participate in a certain year were small general hospitals.
The mean number of admissions significantly increased from
18194 in 2003 to 22899 in 2009 (+25.9%, P¼0.005), whereas
the mean number of patient-days decreased from 116880 in
2003 to 105375 in 2009 (29.8%, P¼0.3). The mean length of
stay significantly decreased from 6.27 days in 2003 to 4.50 days
in 2009 (228.2%, P,0.001). The largest increase in number of
admissions as well as the largest decrease in number of patient-
days was seen in the group of large teaching hospitals.
Hospital use of antibiotics
Trend analysis
In 2003, the mean total systemic use expressed in DDDs per 100
patient-days was 52.3, which significantly increased to 69.8 in
2009 (P,0.001) (Figure 1a). When expressed in DDDs per 100
admissions, mean total systemic use remained almost constant
at 328.2 in 2003 and 314.2 in 2009 (Figure 1b). The same pattern
was also seen in university hospitals, large teaching hospitals and
general hospitals individually. However, a large variation in quanti-
tative antibiotic use was found between the participating hospitals,
in particular in general and large teaching hospitals (Figure 2).
Despite the overall constant use when expressed in DDDs per
100 admissions, we found a significant increase in the total use
of piperacillin/tazobactam, cefazolin, ceftriaxone, meropenem,
azithromycin, gentamicin, ciprofloxacin and vancomycin
(Table 1).
Moreover, the increase in the use of meropenem and vanco-
mycin in each particular type of hospital in both DDDs per 100
patient-days and DDDs per 100 admissions was remarkable.
Expressed in DDDs per 100 patient-days, use of meropenem
increased from 0.72 in 2003 to 1.70 in 2009 (P,0.001) in univer-
sity hospitals, from 0.16 to 0.58 (P,0.001) in large teaching hos-
pitals and from 0.18 to 0.48 (P,0.001) in general hospitals. Use
of vancomycin increased from 1.36 in 2003 to 2.24 in 2009
(P,0.001) in university hospitals, from 0.33 to 1.01 (P,0.001)
in large teaching hospitals and from 0.19 to 0.44 (P,0.001) in
general hospitals. Expressed in DDDs per 100 admissions, use
of meropenem increased from 5.31 in 2003 to 10.38 in 2009
(P,0.001) in university hospitals, from 1.05 to 2.65 (P,0.001)
in large teaching hospitals and from 1.09 to 1.99 (P,0.001) in
general hospitals. Use of vancomycin increased from 9.75 in
2003 to 13.52 in 2009 (P,0.05) in university hospitals, from
2.10 to 4.75 (P,0.05) in large teaching hospitals and from
1.18 to 1.87 (P,0.001) in general hospitals.
DDDs per 1000 inhabitants per day
In 2003, national hospital antibiotic consumption expressed in
DDDs per 1000 inhabitants per day was 0.73, which gradually
increased by 38% to 1.01 in 2009. The increase in the use of
meropenem, vancomycin and ceftriaxone was remarkable
(308%, 233% and 209%, respectively), as was the increase in
the use of colistin (249%), fusidic acid (202%), piperacillin/tazo-
bactam (173%), azithromycin (151%), ceftazidime (90%) and
the aminoglycosides tobramycin and gentamicin (110% and
86%, respectively) (Table 2). Almost 50% of all antibiotics used
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in Dutch hospitals are penicillins (J01C). Other large groups
of antibiotics are the cephalosporins, carbapenems and
monobactams (J01D), and the quinolones (J01M).
Discussion
Total systemic antibiotic use significantly increased from 52.3 in
2003 to 69.8 in 2009 when expressed in DDDs per 100 patient-
days, whereas it remained constant when expressed in DDDs
per 100 admissions. Hospital admissions in this period increased
by 26% and length of stay decreased by 28%. This means that,
on average, individual patients were exposed to the same amount
of antibiotics, but because more patients were admitted to the
hospital per day, total use of antibiotics per hospital increased.
These observations are in line with the study of Liem et al.,3
who described an increase from 47.2 DDDs per 100 patient-days
in 1997 to 58.2 DDDs per 100 patient-days in 2002, and a
constant use when expressed in DDDs per 100 admissions.
A large variation in quantitative antibiotic use was found
between the participating hospitals, in particular in general and
large teaching hospitals. Investigation into the determinants
that cause this variation—e.g. differences in local antibiotic
policy—is warranted.
As stated by Ansari et al.11 and Filius et al.,5 more than one
clinical activity variable should be used as the denominator to
determine changes in antibiotic use in hospitals for better under-
standing of the data. In the present study, Dutch hospital anti-
biotic use is expressed in DDDs per 100 patient-days, DDDs per
100 admissions and, for the first time, DDDs per 1000 inhabi-
tants per day. These data can now be used for cross-national
comparison.6,12 Hospital antibiotic consumption in the Nether-
lands is still low compared with other European countries,
ranging from 0.73 DDDs per 1000 inhabitants per day in 2003
to 1.01 DDDs per 1000 inhabitants per day in 2009.
For example, in 2002, Kern et al.13 estimated the hospital anti-
biotic consumption for Baden-Wurttemberg—a federal state in
2003
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Figure 1. Trend in antibiotic use in Dutch hospitals, 2003–09: university
hospitals (UH) versus large teaching hospitals (LTH) versus general
hospitals (GH). (a) Use in DDDs per 100 patient-days. (b) Use in DDDs
per 100 admissions.
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Figure 2. Variance in total use of antibiotics for systemic use (J01) in
Dutch hospitals, 2009: university hospitals (UH) versus large teaching
hospitals (LTH) versus general hospitals (GH). (a) Use in DDDs per 100
patient-days. (b) Use in DDDs per 100 admissions.
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south-western Germany with 10.6 million inhabitants—to be 2
DDDs per 1000 inhabitants per day. Also in 2002, median nation-
al hospital antibiotic consumption in Europe was 2.1 DDDs per
1000 inhabitants per day, ranging from 1.3 in Norway and
Sweden to 3.9 in Finland and France.6
The decrease in the duration of hospital stay in the
Netherlands has been evident for years and further decreased
during our study period. Our data showed that this decrease is
most evident in large teaching hospitals. Presuming that the dur-
ation of antibiotic therapy for one patient did not change, the
most likely consequence of a shortening of the duration of hos-
pital stay is that the antibiotic therapy is continued extramurally.
This could be subject to further research.
Another consequence of a reduction in the duration of hos-
pital stay is that more patients with antibiotic treatment can
be admitted per bed during a specific period. This results in an
intensification of antibiotic treatment per patient-day and per
hospital bed, which may cause increased selection pressure
towards resistance. Because patients are close to each other in
hospitals, increased selection pressure from one bed to the sur-
rounding environment may lead to the transmission of
antimicrobial-resistant organisms to other patients within a
hospital ward. In particular, the transmission of methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant
enterococci and carbapenem-resistant Acinetobacter baumannii
to other patients may increase.14 – 17 Sites most commonly con-
taminated in hospitals include bedside rails, bedside tables,
blood pressure cuffs, ultrasonic nebulizers, ventilation grills,
floors, toilets and call buttons.14 The contribution of higher anti-
biotic use in these settings to the spread of resistant microorgan-
isms needs further research. Therefore, closer monitoring of
antibiotic consumption and the development of resistance in re-
lation to bed occupancy is warranted.
For meropenem and vancomycin, increases in both DDDs
per 100 patient-days and DDDs per 100 admissions were
observed in each particular type of hospital between 2003 and
2009, as well as in DDDs per 1000 inhabitants per day. One pos-
sible explanation for this increase in the use of meropenem and
vancomycin is the increasing emergence of extended-spectrum
b-lactamase-producing bacteria and methicillin-resistant sta-
phylococci (particularly coagulase-negative species) in Dutch
hospitals.4 This might be a cause for concern, since this trend
towards higher use is more likely to be associated with an in-
crease in selection pressure. For example, in the intensive care
Table 1. Trend in antibiotic use in Dutch hospitals (DDDs per 100 patient-days and DDDs per 100 admissions), 2003–09; selected antibiotics, ATC5
level
ATC code Antibiotic
DDDs per 100 patient-days DDDs per 100 admissions
2003 2009 P value 2003 2009 P value
J01AA02 doxycycline 1.437 1.523 0.503 8.845 6.698 0.089
J01CA04 amoxicillin 5.829 7.159 ,0.001 36.35 32.46 0.302
J01CE01 benzylpenicillin 0.900 1.244 0.048 5.667 5.535 0.624
J01CE05 pheneticillin 0.289 0.286 0.817 1.818 1.318 0.091
J01CF05 flucloxacillin 5.199 6.135 ,0.001 32.84 28.02 0.226
J01CR02 amoxicillin/clavulanic acid 12.24 16.68 ,0.001 76.17 73.24 0.881
J01CR05 piperacillin/tazobactam 0.284 0.644 ,0.001 1.928 2.965 ,0.001
J01DB04 cefazolin 1.571 2.746 ,0.001 9.756 12.34 0.003
J01DC02 cefuroxime 2.987 3.849 0.292 18.48 16.64 0.964
J01DD01 cefotaxime 0.382 0.524 0.942 2.429 2.537 0.999
J01DD02 ceftazidime 0.631 0.842 ,0.001 4.120 3.985 0.316
J01DD04 ceftriaxone 0.744 1.510 ,0.001 4.716 7.373 0.017
J01DH02 meropenem 0.235 0.671 ,0.001 1.547 3.316 ,0.001
J01EA01 trimethoprim 0.530 0.420 0.287 3.296 1.871 0.010
J01EE01 sulfamethoxazole/trimethoprim 2.130 1.858 0.039 13.59 8.598 ,0.001
J01FA09 clarithromycin 1.362 1.094 ,0.001 8.471 4.868 ,0.001
J01FA10 azithromycin 0.256 0.432 ,0.001 1.685 2.070 ,0.001
J01FF01 clindamycin 1.540 2.308 ,0.001 9.757 10.36 0.804
J01GB01 tobramycin 0.626 0.550 0.354 4.189 2.598 0.411
J01GB03 gentamicin 1.672 3.410 ,0.001 10.56 15.17 ,0.001
J01MA02 ciprofloxacin 4.326 7.818 ,0.001 27.45 35.03 ,0.001
J01MA06 norfloxacin 0.934 0.555 0.142 5.883 2.358 ,0.001
J01XA01 vancomycin 0.368 0.871 ,0.001 2.441 4.389 ,0.001
J01XB01 colistin 0.076 0.171 0.340 0.535 0.861 0.586
J01XC01 fusidic acid 0.027 0.060 0.848 0.185 0.283 0.894
J01XD01 metronidazole 1.627 1.893 0.049 10.15 8.485 0.527
J01XE01 nitrofurantoin 0.801 1.129 0.034 4.921 4.980 0.281
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unit, increasing carbapenem use will enhance antibiotic resist-
ance in Pseudomonas aeruginosa.18 Transmission of resistant
microorganisms for these types of antibiotics in particular is pos-
sible via environmental contamination. In brief, although a single
patient may receive an effective antibiotic, the posed antibiotic
selection pressure may create a resistance problem for other
patients in the near future.
For ciprofloxacin, an increase in total use in DDDs per 100
admissions was observed. This drug is associated with MRSA
and Clostridium difficile. Since 2005, there has been an increase
in C. difficile in the Netherlands.19 There is no notable increase
in MRSA due to the very effective ‘search and destroy’ policy in
the Netherlands.20 However, in 2011 there was an increase in
the emergence of MRSA of unknown origin.21 This could mean
a spread through the community. Further research is therefore
warranted.
Extrapolation of the Dutch hospital sample data to a national
aggregate of hospital antibiotic use was not easy. First, con-
sumption patterns show large variability between hospitals.
Second, only 13 hospitals participated every year during our
study period, which means that numerous data were interpo-
lated. For this reason, no trend analysis could be performed.
Also, we did not test the sample’s representativeness of the
Netherlands, which is a flaw of this study. However, our interpo-
lated number of patient-days is nearly identical to the number of
patient-days reported by CBS (data not shown). A possible limita-
tion is that our data were collected by means of a questionnaire.
Finally, a possible source of bias was the variety of methods used
by the different Dutch hospital pharmacies to quantify their anti-
biotic use. Ideally, actual prescription data should be used as a
source to measure antibiotic use in hospitals.
Conclusions
Total hospital antibiotic consumption is still low in the Nether-
lands. Also, the use of antibiotics in individual hospitalized
patients remains stable. However, since they remained in the
hospital for a shorter period of time, the number of DDDs per
100 patient-days increased. This results in an intensification of
antibiotic treatment per hospital bed, leading to a possible in-
crease in selection pressure towards resistance. This may
create a problem for future patients. Therefore, everyone
should be fully aware of the described situation and take this
into consideration when formulating policy around hospital anti-
biotic use. To limit the emergence and transmission of
antimicrobial-resistant bacteria, effective antibiotic stewardship
Table 2. Data on the use of antibiotics for systemic use (J01) in Dutch hospitals in DDDs per 1000 inhabitants per day, 2003–09; selected
antibiotics, ATC5 level
ATC code Antibiotic
Year
Percentage change, 2003–092003 2004 2005 2006 2007 2008 2009
J01AA02 doxycycline 0.021 0.023 0.025 0.025 0.023 0.022 0.023 11
J01CA04 amoxicillin 0.082 0.088 0.101 0.111 0.108 0.099 0.109 33
J01CE01 benzylpenicillin 0.013 0.014 0.016 0.017 0.016 0.015 0.019 46
J01CE05 pheneticillin 0.003 0.004 0.005 0.004 0.004 0.004 0.004 25
J01CF05 flucloxacillin 0.068 0.080 0.089 0.091 0.087 0.086 0.093 37
J01CR02 amoxicillin/clavulanic acid 0.185 0.208 0.225 0.232 0.225 0.220 0.231 25
J01CR05 piperacillin/tazobactam 0.004 0.005 0.006 0.007 0.008 0.009 0.010 173
J01DB04 cefazolin 0.023 0.026 0.032 0.031 0.034 0.033 0.039 67
J01DC02 cefuroxime 0.038 0.045 0.050 0.054 0.049 0.042 0.049 28
J01DD01 cefotaxime 0.008 0.008 0.008 0.008 0.007 0.008 0.008 5
J01DD02 ceftazidime 0.007 0.010 0.012 0.013 0.012 0.012 0.013 90
J01DD04 ceftriaxone 0.008 0.011 0.016 0.019 0.018 0.020 0.025 209
J01DH02 meropenem 0.002 0.004 0.005 0.006 0.007 0.008 0.010 308
J01EA01 trimethoprim 0.008 0.008 0.009 0.009 0.009 0.007 0.006 218
J01EE01 sulfamethoxazole/trimethoprim 0.030 0.032 0.035 0.034 0.033 0.029 0.030 0
J01FA09 clarithromycin 0.018 0.020 0.022 0.019 0.018 0.015 0.016 28
J01FA10 azithromycin 0.003 0.003 0.005 0.006 0.008 0.008 0.007 151
J01FF01 clindamycin 0.023 0.027 0.030 0.031 0.031 0.029 0.033 40
J01GB01 tobramycin 0.005 0.007 0.010 0.010 0.009 0.012 0.011 110
J01GB03 gentamicin 0.024 0.024 0.027 0.028 0.031 0.036 0.044 86
J01MA02 ciprofloxacin 0.066 0.077 0.086 0.093 0.101 0.119 0.109 66
J01MA06 norfloxacin 0.012 0.013 0.012 0.012 0.010 0.009 0.009 224
J01XA01 vancomycin 0.004 0.006 0.009 0.010 0.010 0.011 0.014 233
J01XB01 colistin 0.001 0.001 0.003 0.002 0.002 0.003 0.003 249
J01XC01 fusidic acid 0.000 0.000 0.000 0.000 0.000 0.001 0.001 202
J01XD01 metronidazole 0.023 0.024 0.024 0.027 0.027 0.025 0.026 13
J01XE01 nitrofurantoin 0.012 0.014 0.017 0.016 0.018 0.016 0.017 42
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is essential. Specifically, deliberate use of meropenem and
vancomycin is recommended. The emphasis should be on the
principle that they should only be used when the correct indica-
tion is present. More research is needed to determine the rela-
tionship between antibiotic use, environmental contamination,
selection pressure and the emergence of resistance.
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